Alqatari Safi, Alqunais Abdulaziz A, Alali Shahad M, Alharbi Mohammed A, Hasan Manal, Al Shubbar Mohammed D
Rheumatology Division, Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
J Clin Med. 2024 Nov 19;13(22):6970. doi: 10.3390/jcm13226970.
VEXAS syndrome is a recently identified autoinflammatory disorder resulting from somatic mutations in the UBA1 gene, leading to a complex spectrum of severe inflammatory and hematologic manifestations. The absence of established treatment guidelines and the variability in clinical presentation make its management particularly challenging. Current therapeutic approaches are often based on limited evidence, and their effectiveness remains inconsistent. This review seeks to consolidate the existing knowledge on therapeutic strategies for VEXAS syndrome, offering a critical evaluation of their efficacy and addressing the gaps in the current literature. As the clinical recognition of VEXAS grows, there is an urgent need to explore more targeted, effective treatments that can address both the inflammatory and hematologic aspects of the disease. By providing a comprehensive analysis of the current therapeutic landscape, this review aims to guide clinicians and researchers toward developing more effective, long-term management strategies for this life-threatening condition.
VEXAS综合征是一种最近才被确认的自身炎症性疾病,由UBA1基因的体细胞突变引起,导致一系列复杂的严重炎症和血液学表现。由于缺乏既定的治疗指南以及临床表现的变异性,其管理极具挑战性。目前的治疗方法往往基于有限的证据,其有效性也不一致。本综述旨在整合关于VEXAS综合征治疗策略的现有知识,对其疗效进行批判性评估,并填补当前文献中的空白。随着对VEXAS综合征临床认识的增加,迫切需要探索更有针对性、有效的治疗方法,以解决该疾病的炎症和血液学方面的问题。通过对当前治疗前景进行全面分析,本综述旨在指导临床医生和研究人员为这种危及生命的疾病制定更有效、长期的管理策略。